BOULDER, Colo., Feb. 16, 2016 (SEND2PRESS NEWSWIRE) -- Terrapin Care Station, with dispensaries in Boulder and Aurora, Colo., begins a new year with the launch of two cannabis products that incorporate innovative packaging design with child resistance, product protection, and portability.
OAKLAND, Calif., Oct. 19, 2015 (SEND2PRESS NEWSWIRE) -- Council for Vaccine Safety, and A Voice for Choice, in collaboration with community leaders, announce that on October 24, 2015 at 12 noon, protesters will rally at Frank Ogawa Plaza in Oakland, Calif. in solidarity with the Truth, Transparency and Freedom Rally happening on the same day at the CDC in Atlanta, Georgia.
RxQ Antioxidant Complex for Those Faced with Excessive Oxidative Stressors from Busy and Stressful Lifestyle
SAN PEDRO, Calif., July 17, 2015 (SEND2PRESS NEWSWIRE) -- Schoenwetter Supplements, LLC is excited to announce the release of an advanced concept formulation of antioxidants, RxQ Antioxidant Complex. Its proprietary antioxidant formula takes into consideration not only adding antioxidants that can rapidly be depleted but is mindful of the necessary other constituents that serve to help recycle some important antioxidant systems that are everywhere present in our bodies.
NEW YORK, N.Y., Feb. 11, 2015 (SEND2PRESS NEWSWIRE) -- Ellen Relkin, of counsel attorney with Weitz and Luxenberg, P.C., has been named to the plaintiffs' steering committee created by judicial order to facilitate lawsuits against the makers of the anticoagulant drug Xarelto, the personal injury and mass tort law firm today announced.
PORTLAND, Ore., Oct. 15, 2014 (SEND2PRESS NEWSWIRE) -- Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic pharmaceuticals, devices and therapies, will be exhibiting at the American Academy of Ophthalmology (Booth #4550) in Chicago, Ill., on October 18 - 21.
PLYMOUTH, Minn., Oct. 14, 2014 (SEND2PRESS NEWSWIRE) -- SilkTears, LLC, a privately held, research-based and product-driven biotechnology company, announced today that advances in protein-based excipient technology may allow for the development of artificial tear products that will more closely represent certain characteristics of the natural makeup of the tear film, and may help the significant population of patients suffering from dry eye syndrome.